News stories about Sunshine Heart (NASDAQ:CHFS) have been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Sunshine Heart earned a news impact score of 0.06 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.3206109594197 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:

A number of equities research analysts have issued reports on CHFS shares. Zacks Investment Research upgraded shares of Sunshine Heart from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Wednesday, January 17th. ValuEngine upgraded shares of Sunshine Heart from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 31st.

Sunshine Heart (NASDAQ:CHFS) traded down $0.05 on Friday, hitting $3.08. 87,297 shares of the stock were exchanged, compared to its average volume of 473,204. Sunshine Heart has a one year low of $2.87 and a one year high of $99.80. The firm has a market cap of $5.54, a P/E ratio of -0.02 and a beta of 2.34.

WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at

Sunshine Heart Company Profile

CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Insider Buying and Selling by Quarter for Sunshine Heart (NASDAQ:CHFS)

Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with's FREE daily email newsletter.